Stephanie Richards is a partner in Goodwin’s nationally recognized Life Sciences group, counseling public and private companies at all stages of maturity as well as venture capital firms and investment banks across the life sciences industry. 

Ms. Richards advises clients on startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, mergers and acquisitions, and other complex transactions. She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance, capital raising and corporate governance matters. She joined Goodwin in 2018.
Areas of Practice
Domaines D’Expertise





Ms. Richards’ recent client representations include the following:

Capital Markets

  • Aura Biosciences in its $75.6 million initial public offering 
  • Ikena Oncology in its $133.6 million initial public offering and in its $100 million “at-the-market” offering
  • Olink Holding AB (publ) in its $264 million initial public offering and $232.5 million secondary public offering
  • iTeos Therapeutics in its $201 million initial public offering
  • The underwriters in Freeline Therapeutics Holdings plc’s $159 million initial public offering
  • Xeris Pharmaceuticals in its $85.5 million initial public offering, subsequent debt and equity follow on offerings and acquisition of Strongbridge Biopharma plc
  • TCR2 Therapeutics in its $75 million initial public offering and subsequent equity follow on offerings

Venture Capital Financings

  • Repertoire Immune Medicines in its $189 million Series B financing
  • Aura Biosciences in its $80 million Series E financing
  • Ikena Oncology in its $120 million Series B financing
  • Faze Medicines in its $81 million Series A financing
  • Thrive Earlier Detection Corp. in its $110 million Series A financing and $257 million Series B financing
  • iTeos Therapeutics in its $125 million Series B financing
  • Third Rock Ventures in connection with their portfolio investments and related matters

Mergers and Acquisitions

  • Valo Health in its announced 2021 deSPAC business combination with Khosla Ventures Acquisition Co. ($2.8 billion)
  • Cogen Immune Medicines in its merger with Torque Therapeutics
  • ProKidney and its lead investor, Pablo Legorreta, founder and CEO of Royalty Pharma, in the acquisition of inRegen and Twin City Bio, LLC
  • Adhaere Pharmaceuticals in its sale to Gossamer Bio

In The News









J.D./LL.M., 2013
Duke University School of Law
B.A., English, 2010
Yale College



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique